
    
      Test drug:Recombinant humanized anti VEGF monoclonal antibody injection; Research Phase:Phase
      I; Subjects:Subjects with neovascular (wet) age-related macular degeneration; Number of
      Subjects:24; Trial design:Single center, non randomized, open, single arm, single dose, dose
      escalation; Research objective:to rearch the safety and tolerance of JY028 injection;to
      rearch PK of JY028 injection;to observe the efficacy of JY028 in the treatment of nAMD;to
      rearch the relationship between plasma VEGF concentration and JY028 concentration. to rearch
      immunogenicity of JY028;
    
  